Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia

• Published in: Emerging microbes & infections Vol. 9; no. 1; pp. 727 - 732
• Main Authors: Lin, Ling, Lu, Lianfeng, Cao, Wei, Li, Taisheng
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2020; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Animals; Antibodies, Viral - blood; Antibodies, Viral - immunology; Anticoagulants; Anticoagulants - therapeutic use; anticoagulation; Antiviral drugs; B-Lymphocytes - immunology; Betacoronavirus - pathogenicity; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; Coronavirus Infections - therapy; Coronavirus Infections - virology; Coronaviruses; COVID-19; Cytokines - immunology; Cytokines - metabolism; Disease transmission; Epidemics; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Immunoglobulins, Intravenous - therapeutic use; Immunologic Factors - therapeutic use; Infections; Influenza A Virus, H1N1 Subtype; Influenza, Human - immunology; IVIg; Mice; Middle East Respiratory Syndrome Coronavirus - immunology; Pandemics; Pathogenesis; Pneumonia; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; Pneumonia, Viral - therapy; Pneumonia, Viral - virology; Review; SARS Virus - immunology; SARS-CoV-2; Severe Acute Respiratory Syndrome - immunology; Severe acute respiratory syndrome coronavirus 2; T-Lymphocytes - immunology; COVID-19; pathogenesis; IVIg; SARS-CoV-2; anticoagulation

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwi...